
|Videos|August 3, 2021
Complementary use of mpMRI and genomic testing in prostate cancer
Author(s)Urology Times staff
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.
Advertisement
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
ORIC-944 shows promise in combination with ARPIs for mCRPC
2
Jason Hafron, MD, recaps prostate cancer data from ESMO 2025
3
Beyond PSA: Jonathan Henderson, MD, on precision tools for prostate cancer
4
Radioligands and ADT alternatives emerge in prostate cancer treatment
5



















